News
January 19, 2022
Global think tank on the clinical considerations & management of lipoprotein(a): The top questions and answers regarding what clinicians need to know published online in Progress in Cardiovascular Disease
The outcomes of a Global think tank on the clinical considerations & management of lipoprotein(a): The top...
Read More...December 22, 2021
FDA approves Leqvio (inclisiran), first-in-class small interfering RNA therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-Cholesterol
Novartis announced that the U.S. Food and Drug Administration (FDA) approved Leqvio (inclisiran) as an adjunct to diet...
Read More...December 9, 2021
NLA Window to Nominate for Board Leadership Now Open
The National Lipid Association has opened the nomination window for a position on the NLA Board of Directors or Chapter...
Read More...September 24, 2021
Lipid Measurements in the Management of CardioLipid Measurements in the Management of Cardiovascular Diseases: Scientific Statementvascular Diseases: Scientific Statement
Read More...